Search
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigationalFremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnAcetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. … It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. It has been canceled and withdrawn from the market since August 12, 1997.[L1113]
Tropicamide
go.drugbank.com/drugs/DB00809ApprovedTropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. … [L32178] Oral tropicamide has been investigated as a potential drug to relieve sialorrhea in patients with Parkinson's Disease.[A229958]
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnBromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.
Sotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigationalSotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992. … [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexInternational brands: Xi An LinTiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigationalTiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). … [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized
Paramethasone
go.drugbank.com/drugs/DB01384ExperimentalA glucocorticoid with the general properties of corticosteroids.
Quazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitQuazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Sennosides
go.drugbank.com/drugs/DB11365ApprovedInvestigationalIt is a weaker laxative than bisacodyl or castor oil[A177092]. … Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery.
Salts: Sennosides A and BGadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigationalEthoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection.
Categories: Compounds used in a research, industrial, or household setting